Osteogenesis Imperfecta, Type I

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ultragenyx Pharmaceutical
1 program
1
setrusumabPhase 2Monoclonal Antibody
Mereo BioPharma
Mereo BioPharmaUK - London
1 program
1
setrusumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03118570Completed112Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mereo BioPharmasetrusumab

Clinical Trials (1)

Total enrollment: 112 patients across 1 trials

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Start: Sep 2017Est. completion: Nov 2020112 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space